Stock 4743 ONENESS BIOTECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Oneness Biotech Co., Ltd. Stock

Equities

4743

TW0004743000

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-16 pm EDT 		5-day change 1st Jan Change
158 TWD -0.63% Intraday chart for Oneness Biotech Co., Ltd. -9.71% -18.77%
Mar. 29 Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol to Taiwan FDA for Subcutaneous Injection Formulation ofFB825 in Patients with Moderate-To-Severe Atopic Dermatitis CI
Mar. 11 Oneness Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 1.34B 41.51M Sales 2025 * 309M 9.54M Capitalization 71.66B 2.21B
Net income 2024 * -82M -2.53M Net income 2025 * -890M -27.47M EV / Sales 2024 * 49.5 x
Net cash position 2024 * 5.11B 158M Net cash position 2025 * - 0 EV / Sales 2025 * 232 x
P/E ratio 2024 *
-878 x
P/E ratio 2025 *
-80.6 x
Employees 43
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.81%
More Fundamentals * Assessed data

Chart Oneness Biotech Co., Ltd.

Dynamic Chart

Latest news about Oneness Biotech Co., Ltd.

Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol to Taiwan FDA for Subcutaneous Injection Formulation ofFB825 in Patients with Moderate-To-Severe Atopic Dermatitis CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol Forsubcutaneous Injection Formulation of FB825 in Patientswith Moderate-To-Severe Atopic Dermatitis CI
Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Oneness Biotech Co., Ltd. Announces Approval of FESPIXON CI
Oneness Submits Medical Device Registration Application of Bonvadis for Wound Care to the Thai Food and Drug Administration in Thailand CI
Oneness Biotech Co., Ltd. Submits 510(k) Application to the U.S. FDA to Expand the Intended Patient Population and Add Multiple Chronic Wound Indications for Bonvadis CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Oneness Biotech Co., Ltd. Obtains Import License for Bonvadis, The Wound Care Topical Cream in South Africa CI
Oneness Biotech Co., Ltd. Announces Submission of Registration Application for Bonvadis, the Wound Care Topical Cream to the Drug Regulatory Authority of Pakistan CI
US FDA agrees to proceed with Phase 2 clinical trial for SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio CI
Oneness Biotech Co., Ltd. Receives Approval from Malaysia NPRA for FESPIXON, the New Drug in Treatment of Diabetic Footulcers CI
Oneness Biotech Co., Ltd. Announces the National Agency of Drug and Food Control Accepts the NDA Application of the Diabetic Foot Ulcer New Drug, Fespixon CI
Oneness Biotech Co., Ltd. Submits IND to US FDA for a Phase II Clinical Trial on the Broad-Spectrum Anti-SARS-CoV-2siRNA Co-Developed with Microbio CI
More news

Press releases Oneness Biotech Co., Ltd.

Oneness Biotech : The Drug Administration of Vietnam has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon PU
Oneness Biotech : announces the information about the investor's conference of 2022 Q2. PU
Oneness Biotech : The findings of the MoA studies on Fespixon(ON101) under collaboration with TMU and NYCU have been accepted and published by a renown SCI journal, JID Innovations PU
Oneness Biotech : receives a China patent on antagonistic PDL1 aptamers. PU
Oneness Biotech : The Annual General Shareholders' Meeting approved the removal of non-competition restriction on the newly-elected director. PU
More press releases

Quotes and Performance

1 day-0.63%
1 week-9.71%
Current month-9.97%
1 month-5.95%
3 months-8.41%
6 months-12.22%
Current year-18.77%
More quotes

Highs and lows

1 week
157.00
Extreme 157
177.00
1 month
157.00
Extreme 157
180.00
Current year
157.00
Extreme 157
196.00
1 year
157.00
Extreme 157
253.50
3 years
136.67
Extreme 136.6729
297.08
5 years
17.05
Extreme 17.0511
418.81
10 years
16.70
Extreme 16.6996
418.81
More quotes

Managers and Directors - Oneness Biotech Co., Ltd.

Managers TitleAgeSince
Shan Nei Huang CEO
 Chief Executive Officer 80 15-06-25
Chih Hui Cheng CEO
 Chief Executive Officer - 18-06-20
Wen Tzu Hsiao DFI
 Director of Finance/CFO - 19-09-30
Members of the board TitleAgeSince
Chih Hui Cheng CEO
 Chief Executive Officer - 18-06-20
Hsien Shou Kuo BRD
 Director/Board Member 82 10-04-25
Shih Hua Hsu BRD
 Director/Board Member - 12-06-26
More insiders

ETFs positioned on Oneness Biotech Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.02% 4 M€ -4.41% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.01% 117 M€ -1.49% -
More ETFs positioned on Oneness Biotech Co., Ltd.

Quotes

Date Price Change Volume
24-04-17 158 -0.63% 2,268,559
24-04-16 159 -4.22% 4,853,684
24-04-15 166 -3.49% 3,004,630
24-04-12 172 -1.99% 2,063,338
24-04-11 175.5 +0.29% 1,755,271

End-of-day quote Taipei Exchange, April 16, 2024

More quotes

Company Profile

ONENESS BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the research, development, production and sales of health products. The Company's main products include health supplies, health food and healthy food. The Company is also involved in the development of new drugs for the treatment of wound healing in chronic diabetic foot ulcers, as well as the development of new anticancer drugs. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-08 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Oneness Biotech Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
158 TWD
Average target price
262 TWD
Spread / Average Target
+65.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ONENESS BIOTECH CO., LTD. Stock Oneness Biotech Co., Ltd.
-18.77% 2.21B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+28.79% 676B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.78% 554B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.64% 349B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.00% 318B
ABBVIE INC. Stock AbbVie Inc.
+5.99% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.28% 210B
NOVARTIS AG Stock Novartis AG
-0.11% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-9.69% 194B
PFIZER, INC. Stock Pfizer, Inc.
-11.71% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4743 Stock